RAS question
Biosimilars differ from generic drugs in that:
Correct answer: (D) They are similar but not identical copies of complex biological medicines.
Biosimilars are highly similar, but not identical, versions of complex biological medicines that are compared with an approved reference biologic.
Explanation
Biosimilars differ from generic drugs because they relate to biologics, not ordinary small-molecule medicines. The FDA explains that biologics are generally large, complex molecules made from living sources, so they naturally contain slight variations and are more difficult to copy exactly. A biosimilar is therefore approved by showing that it is highly similar to an existing approved reference biologic and has no clinically meaningful differences in safety, purity and potency. By contrast, generic drugs usually involve smaller, simpler active ingredients that are more straightforward to copy. This is why option D captures the key distinction: biosimilars are close matches to complex biological medicines, but they are not exact chemical duplicates.
Why the other options are wrong
- (A) Biosimilars are not defined by being made only from plant sources; the FDA describes biologics as products made from living sources such as bacteria, yeast and animal cells.
- (B) Chemically identical copies of small-molecule drugs describe generic drugs, whereas biosimilars are versions of complex biologics that cannot usually be copied exactly.
- (C) Biosimilars do have regulatory approval: the FDA evaluates a proposed biosimilar against a reference product to verify high similarity and no clinically meaningful differences in safety, purity and potency.
Concept
This tests biotechnology and pharmaceutical regulation, especially the distinction between biologics, biosimilars and generics. It recurs in RAS because science-and-technology questions often link basic molecular complexity with public-health regulation.